LACTOLOGY FOUNDATION

This web-page monograph provides an English, web-oriented toxicological-lactological overview of all medicines classified in ATC A04AD “Other antiemetics,” with emphasis on mechanisms, clinical applications, and safety in lactation.medpedia.framar+2

Position in ATC and pharmacological scope

The ATC class A04 “Antiemetics and antinauseants” belongs to the anatomical group A “Alimentary tract and metabolism” and includes drugs used to prevent or treat nausea and vomiting of diverse origin.wikipedia+1
Within this class, A04AD “Other antiemetics” groups pharmacologically heterogeneous substances that do not fit into serotonin 5‑HT3 antagonists or dopamine antagonists but exert antiemetic effects via muscarinic, histamine H1, cannabinoid and neurokinin‑1 (NK1) receptor pathways.atccode+2
The subgroup comprises classical antimuscarinics, inorganic compounds, sedative adjuvants, dopamine antagonists, cannabinoids, selective NK1 antagonists, and fixed combinations, used mainly in motion sickness, chemotherapy‑induced nausea and vomiting (CINV), and refractory vomiting.medpedia.framar+2

Pharmacological subclasses and mechanisms

D2-receptor antagonists in A04AD (e.g. metopimazine) block dopamine D2 receptors in the chemoreceptor trigger zone and are particularly useful in vomiting induced by cytotoxic chemotherapy and other emetogenic drugs.atcddd.fhi+1
H1-receptor antagonists with antiemetic properties in this context are mainly used for vestibular-related nausea, motion sickness, and vomiting provoked by gastric mucosal irritation, although many are classified in R06 rather than A04AD.atcddd.fhi+2
M‑cholinoreceptor antagonists such as scopolamine act centrally and peripherally at muscarinic receptors, effectively preventing motion sickness and nausea triggered by stimuli that irritate the gastric mucosa.medlineplus+2
Antagonists of neurokinin‑1 receptors, such as aprepitant and related agents, show high efficacy in cytotoxic‑induced nausea and vomiting by selectively inhibiting substance P binding in the vomiting center and chemoreceptor trigger zone.iris.who+2

Individual ATC A04AD entries (concise)

According to WHO/ATC‑DDD and current indexes, the following medicines are classified in A04AD “Other antiemetics.”atcddd.fhi+2

The veterinary code QA04AD90 (maropitant) represents a selective NK1 receptor antagonist widely used in dogs and cats for acute vomiting and motion sickness, but it is outside the human A04AD scope.wikipedia

Toxicological profile relevant to lactation

From a toxicological-lactological perspective, A04AD drugs include centrally acting agents with potential anticholinergic, dopaminergic, cannabinoid and NK1-mediated adverse effects, many of which may theoretically affect nursing infants if transferred into breast milk.australianprescriber.tg+2
Scopolamine can cause antimuscarinic adverse reactions such as dry mouth, blurred vision, confusion, hallucinations, urinary retention, and, as recently highlighted by FDA and MedlinePlus, hyperthermia with reduced sweating, mainly in children and older adults.fda+1
Because of its central anticholinergic actions and risk of CNS effects, scopolamine should be used cautiously in breastfeeding, especially with transdermal systems that deliver sustained doses and may accumulate in maternal tissues and breast milk; close monitoring of the infant for sedation, irritability, and poor feeding is advisable if exposure cannot be avoided.fda+1

Dopamine antagonists such as metopimazine share class-related adverse effects including extrapyramidal symptoms (acute dystonia, akathisia), sedation, hypotension and, rarely, neuroleptic malignant syndrome, and in lactating women they may theoretically alter prolactin secretion and milk production.best.barnsleyccg+1
Cannabinoids (dronabinol and nabilone) can produce CNS depression, euphoria, dysphoria, impaired psychomotor performance, and cardiovascular effects; THC and related cannabinoids are known to pass into breast milk, where chronic exposure has been associated with potential neurodevelopmental risks in infants, so their use in breastfeeding women is typically discouraged unless benefits clearly outweigh risks.clevelandclinic+1
NK1 antagonists such as aprepitant and rolapitant generally have favorable tolerability profiles, with common adverse effects including fatigue, hiccups, constipation and mild transaminase elevations, and limited data suggest low to moderate transfer into breast milk; however, due to the paucity of lactation-specific evidence, they should be reserved for cases where CINV cannot be controlled with agents considered more established in breastfeeding.australianprescriber.tg+1

Overall, when selecting an A04AD agent for a nursing mother, preference should be given to drugs with short half‑life, extensive clinical experience and established lactation safety, minimizing use of long‑acting central anticholinergics and cannabinoids, and avoiding combinations that add unnecessary sedative load.clevelandclinic+1
Non-pharmacological measures (dietary modification, ginger preparations, acupressure) and alternative antiemetic classes with better characterized lactation profiles may be considered first-line before resorting to A04AD drugs, especially in mild to moderate nausea.best.barnsleyccg+1

Clinical and lactation-oriented notes for healthcare professionals

For scopolamine patches, recent regulatory warnings emphasize the risk of hyperthermia and heat-related complications, particularly in children and older adults, which is essential when counseling breastfeeding women who may care for infants in warm environments or use external heat sources.medlineplus+1
If a nursing mother requires scopolamine for severe motion sickness, clinicians should minimize duration, use the lowest effective dose, avoid additional anticholinergics, and monitor both mother and infant for reduced sweating, fever, lethargy, and feeding changes.fda+1

Chemotherapy regimens frequently combine 5‑HT3 antagonists, corticosteroids and NK1 antagonists; in breastfeeding patients, multidisciplinary evaluation (oncology, neonatology, lactation specialist) is advised to weigh maternal benefits against potential infant exposure and to consider temporary interruption of breastfeeding when highly emetogenic regimens and A04AD agents are mandatory.iris.who+2
Cannabinoid antiemetics should be regarded as later‑line options in lactating patients, and when used, detailed informed consent and documentation of counseling regarding possible infant neurodevelopmental risks are recommended.drugbank+1

The heterogeneous nature of A04AD implies that toxicological and lactation safety cannot be generalized across the subgroup; each substance requires individual risk assessment, considering pharmacokinetics, receptor profile, and available human data, before inclusion in a toxicological‑lactological database for clinical use.medpedia.framar+2